Showing 921 - 940 results of 40,013 for search '(( 50 ((we decrease) OR (((a decrease) OR (mean decrease)))) ) OR ( a de decrease ))', query time: 1.35s Refine Results
  1. 921
  2. 922

    Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>In the recurrence group, mean outpatient visits (± standard deviation) decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  3. 923
  4. 924

    Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  5. 925

    Annual number of outpatient visits in all eyes. by Yasuyuki Sotani (20114144)

    Published 2025
    “…<p>Mean visit frequency (mean ± standard deviation) significantly decreased from 11.5 ± 4.3 preoperatively to 8.8 ± 4.1, 5.0 ± 3.4, and 4.4 ± 3.2 visits in the first, second, and third postoperative years, respectively (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”
  6. 926

    Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

    Published 2025
    “…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”
  7. 927
  8. 928
  9. 929
  10. 930
  11. 931
  12. 932
  13. 933

    <i>Trans ε</i> viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model by Martial Caillaud (6383672)

    Published 2019
    “…Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that <i>trans ε</i>-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age.…”
  14. 934
  15. 935

    Optical Phenomena and Antifrosting Property on Biomimetics Slippery Fluid-Infused Antireflective Films via Layer-by-Layer Comparison with Superhydrophobic and Antireflective Films by Kengo Manabe (1437730)

    Published 2014
    “…A slippery fluid-infused antireflective film composed of chitin nanofibers less than 50 nm in diameter prevented light scattering at the long-wavelength side by Rayleigh scattering to achieve 97.2% transmittance. …”
  16. 936
  17. 937
  18. 938

    The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5. by Ya-Ping Wang (44525)

    Published 2015
    “…<p>The mean <i>z</i>-coordinate error decreasing percentages (%) of SSI-RIK compared to EM-SFM, CSF and RIK, when the sequence sizes vary from 15 to 50 with an equal interval 5.…”
  19. 939
  20. 940